Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 17004 participants.
Also called NCT05030428
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 17,004 participants
- Sponsor
- Registry
-
NCT05030428
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Greece, Hungary, Iceland, India, Israel, Italy, Japan, Kenya, Latvia, Lithuania, Malaysia, Mauritius, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05030428. Randomized; double masking; primary purpose treatment. Start 2021-11-23 (actual); primary completion 2027-05-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
- Acronym
- VICTORION-2P
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Inclisiran sodium 300 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05030428- Content hash
1ed419ef8e4656e54aebf474ea64745b0be336dc82f822923e52c8aa82fb5ad0